SCHEMBL2114477

SCHEMBL2114477

O=C1Oc2ccccc2Oc2cc(O)ccc21

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOA P21397 6/20 0.49
MAOB P27338 5/20 0.49
CISD1 Q9NZ45 1/20 0.49
MEN1 O00255 6/20 0.47
KMT2A Q03164 6/20 0.47
RECQL P46063 3/20 0.47
TDP1 Q9NUW8 2/20 0.47
MAPT P10636 2/20 0.47
HPGD P15428 1/20 0.47
CYP2C19 P33261 1/20 0.47
HTT P42858 1/20 0.47
BLM P54132 1/20 0.47
SMAD3 P84022 1/20 0.47
PRMT1 Q99873 1/20 0.47
ACE2 Q9BYF1 1/20 0.47
FTO Q9C0B1 1/20 0.47
TYR P14679 4/20 0.46
TRPA1 O75762 1/20 0.45
USP2 O75604 2/20 0.44
POLB P06746 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14259795 0.92 MAOA (0.49) MAOAMAOBCISD1MEN1KMT2A
SCHEMBL6984812 0.80 MAOA (0.57) MAOAMAOBCISD1MEN1KMT2A
SCHEMBL18417129 0.79 AHR (0.54) MAOAMAOBCISD1MEN1KMT2A
SCHEMBL11091875 0.77 AHR (0.54) MAOAMAOBKMT2ATDP1MAPT
SCHEMBL2113335 0.77 ALOX15 (0.57) MAOAMAOBMEN1KMT2ARECQL
SCHEMBL30055520 0.77 ALOX15 (0.57) MAOAMAOBMEN1KMT2ARECQL
SCHEMBL7112829 0.76 ALDH1A1 (0.49) MAOAMAOBCISD1MEN1KMT2A
SCHEMBL23460330 0.75 MAOA (0.43) MAOAMAOBCISD1MEN1KMT2A
SCHEMBL29919352 0.75 MAOA (0.43) MAOAMAOBCISD1MEN1KMT2A
SCHEMBL5150419 0.73 HSD17B10 (0.41) MAOAMAOBCISD1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8158623-B2 Heptacyclic compounds and the pharmaceutical uses thereof for preventing and treating diabetes and metabolic syndrome SHANGHAI INSTITUTE OF MATERIA MEDICA CHINESE ACADEMY OF SCIENCES (CN) 2012-04-17 US disclosed
US-20100173905-A1 HEPTACYCLIC COMPOUNDS AND THE PHARMACEUTICAL USES THEREOF FOR PREVENTING AND TREATING DIABETES AND METABOLIC SYNDROME SHANGHAI INSTITUTE OF MATERIA MEDICA CHINESE ACADEMY OF SCIENCE 2010-07-08 US disclosed
EP-2199295-A1 COMPOUNDS WITH 7-MEMBER CYCLE AND THE PHARMACEUTICAL USE THEREOF FOR PREVENTING AND TREATING DIABETES AND METABOLISM SYNDROME Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CN) 2010-06-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100173905-A1 HEPTACYCLIC COMPOUNDS AND THE PHARMACEUTICAL USES THEREOF FOR PREVENTING AND TREATING DIABETES AND METABOLIC SYNDROME GPR119, CYP11B1, HSD11B1 MAOA 3178/4885MAOB 3061/4885CISD1 3003/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.